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Mitogen-activated protein (MAP) kinases are critical mediators in signal transduction pathways regulating embryogenesis, cell differentiation, cell proliferation, and cell death in response to extracellular stimuli and stress.
3,4 Extracellular signal-regulated kinase (ERK), p38, and c-Jun Nterminal kinase (JNK) are the major mammalian MAP kinases that are regulated by some of protein tyrosine phosphatase (PTP) family members. PTP superfamily comprises 107 enzymes. Based on the amino acid sequences of their catalytic domains, the PTPs can be grouped into four main families: (i) classical PTPs and dual-specificity phosphatases (DUSPs), (ii) tyrosine-specific low molecular weight phosphatases, (iii) the cdc25 family, and (iv) Eyes absent (EyA) protein that was recently discovered to be tyrosine-, or dual serine-and tyrosine-specific protein phosphatases.
1 DUSPs are a subfamily of mammalian class I cysteine-based PTP superfamily, which dephosphorylate both tyrosine and serine/ threonine residues. Some DUSPs have been characterized for the role in MAPK signaling pathways. 5 Since PTPs play critical roles for cell homeostasis, chemical inhibitors that regulate DUSPs have been extensively investigated to be used as therapeutic reagents.
PRL-3 inhibitor I is a rhodanine derivative and inhibits phosphatase of regenerating liver-3 (PRL-3) in vitro.
6 PRL-3 is a nonclassical protein tyrosine phosphtase and overexpression of PRL-3 plays a role in tumorigenesis and metastasis in various types of cancer cells. PRL-3 is associated with promoting cell motility, invasion activity, and metastasis. However, the biological and mechanistic evidence for PRL-3 function has not been understood well. 7, 8 The half maximal inhibitory concentration (IC 50 ) of PRL-3 inhibitor I is known to be 0.9 μM against PRL-3 ( Fig. 1(a) ). To investigate the role of PRL-3 inhibitor I on other PTPs, we performed in vitro phosphatase assays with purified recombinant PTPs ( Table 1) . We identified that dualspecificity phosphatase 22 (DUSP22) is inhibited by PRL-3 inhibitor I while other PTPs are not.
DUSP22, also called JNK-stimulatory phosphatase 1 (JSP1) and JNK pathway-associated phosphatase (JKAP), positively regulates MAPK signaling pathways in contrast to most phosphatases which negatively regulate MAPK signaling pathways.
9 Overexpression of DUSP22 in HEK 293T cells activated JNK but not p38 and ERK. 10 Activation of JNK by DUSP22 is associated with activation of MKK4 which is an immediate JNK upstream activating kinase. In addition, a kinase inactive form of MKK4 (MKK4KR) abolished DUSP22-induced activation of JNK in COS-1 cells. Furthermore, the inactive mutant of DUSP22 failed to induce JNK activation.
11 This suggests that DUSP22 does not directly activate JNK but supports an enzyme activity of kinase upstream of MKK4.
11 Since DUSP22 is a specific regulator of JNK activation in response to stress, growth, and apoptosis, regulators of JNK activation like DUSP22 can be a reasonable therapeutic drug target.
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The phosphatase activity of DUSP22 was decreased by PRL-3 inhibitor I in a dose-dependent manner, whereas others were not (data not shown). The half maximal inhibitory concentration (IC 50 ) of DUSP22 was determined about 3.46 ± 0.55 μM by the curve fitting program Prism 3.0 (GraphPad Software) (Fig. 1(b) ). Next, we confirmed that DUSP22 is involved in the regulation of JNK signaling and PRL-3 inhibitor I inhibits DUSP22 activity towards JNK. To examine whether DUSP22 plays a role as a JNK activator in vivo, HEK 293 cells were transfected with FLAG-tagged DUSP22 wild-type (WT) expression plasmid. After 48 h of transfection, cells were treated with various concentrations of PRL-3 inhibitor I for 3 h. Then the levels of endogenous phospho-JNK were determined with immunoblotting analysis. As shown in Figure 2 , we found the level of phospho-JNK was effectively decreased by PRL-3 inhibitor I in a dosedependent manner. The results indicate that PRL-3 inhibitor I reduces the level of phospho-JNK by inhibiting the enzymatic activity of DUSP22.
Taken together, we confirmed DUSP22 was effectively inhibited by PRL-3 inhibitor I in vivo and in vitro and DUSP22-mediated JNK signaling could be controlled by PRL-3 inhibitor I. Since JNK signaling pathway is implicated in critical physiological processes such as embryonic morphogenesis, cell survival, and apoptosis, the regulation of DUSP22-mediated JNK signaling by PRL-3 inhibitor I could be used as therapeutic drugs for JNK signaling linked human diseases such as tumorigenesis, cardiac hypertrophy, ischemia-reperfusion injury, diabetes, hyperglycemia-induced apoptosis, neurodegenerative diseases like Parkinson's disease.
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Experimental Section
Cell Culture and Transfection. Human embryonic kidney (HEK) 293 cells were maintained in Dulbecco's modified Eagle's medium (DMEM, Thermo Scientific, Waltham, MA). All of media were supplemented with 10% fetal bovine serum (FBS, Thermo Scientific) and penicillin/streptomycin in the presence of 5% CO 2 . For transfection, 4 × 10 5 cells were seeded before the day of transfection and transfected with DNA using OmicsFect™ (Omics Biotechnology, Taiwan).
Antibodies and Plasmid Constructions. Anti-JNK was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-phospho-SAPK/JNK (specific for phospho-Thr183 and phosho-Tyr185) was from Cell Signaling Technology (Danvers, MA). Monoclonal Anti-FLAG was from Sigma-Aldrich. Histagged DUSP22-WT was constructed in pET28a plasmid (Novagen, Madison, WI) for protein expression in Escherichia coli and FLAG-tagged DUSP22-WT was constructed in pcDNA3.1 (Invitrogen, Carlsbad, California).
Purification of 6x His Tagged Proteins. PTP expression plasmids were constructed in pET28a(+) and transformed into BL21(DE3)-RIL E. coli. Recombinant proteins were purified as previously described.
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In vitro PTP Activity Assays and Kinetic Analysis. Protein phosphatase activity was measured using the substrate 3-Omethylfluorescein phosphate (OMFP; Sigma, St. Louis, MO) at the approximate Km of the enzyme in a 96-well microtiter plate based on methods described previously.
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PRL-3 inhibitor I and OMFP were solubilized in H 2 O and DMSO, respectively, and all reactions were performed at a final concentration of 1% DMSO. The final reaction mixture (100 µL) was optimized for enzyme activity and comprised of 30 mM Tris-HCl (pH 7), 75 mM NaCl, 1 mM ethylenediaminetetra acetic acid (EDTA), 0.4 mM dithiothreitol (DTT), 0.132% bovine serum albumin (BSA) and 100 nM of PTPs. Reaction immediately begins by addition of OMFP and the incubation time was 30 min at 37 o C using a fluorescence plate reader set at an excitation of 485 nm and emission of 535 nm. Half maximal inhibition constant (IC 50 ) was defined as the concentration of an inhibitor that caused a 50% decrease in the PTP activity. Half-maximal inhibition constants were determined by using the curve fitting program Prism 3.0 (GraphPad Software). All experiments were performed in triplicate and were repeated at least three times.
Immunoblotting Analysis. Transfected cells with or without DUSP22 WT expression plasmid for 48 h were washed twice with phosphate buffered saline (PBS) buffer and lysed in 1x SDS sample buffer (12 mM Tris-HCl pH 6.8, 0.4% SDS, 5% glycerol, 1% β-mercaptoethanol, 0.02% bromophenol blue) and boiled at 100 o C for 5 min. Samples were run in SDS-10% polyacrylamide gels and transferred to nitrocellulose membrane. Then the membranes were blocked with 5% skim milk for 1 h and incubated with an appropriate antibody, followed by incubation with a HRPconjugated secondary antibody. The protein bands were visualized by the ECL detection system (Pierce, Rockford, IL).
